User menu

Health technology assessment in osteoporosis

Bibliographic reference Hiligsmann, Mickael ; Kanis, John A. ; Compston, Juliet ; Cooper, Cyrus ; Flamion, Bruno ; et. al. Health technology assessment in osteoporosis. In: Calcified Tissue International, Vol. 93, no. 1, p. 1-14 (2013)
Permanent URL
  1. Abrahamsen B., van Staa T., Ariely R., Olson M., Cooper C., Excess mortality following hip fracture: a systematic epidemiological review, 10.1007/s00198-009-0920-3
  2. Kanis John A., Oden Anders, Johnell Olof, De Laet Chris, Jonsson Bengt, Excess mortality after hospitalisation for vertebral fracture, 10.1007/s00198-003-1516-y
  3. Hiligsmann Mickaël, Bruyère Olivier, Ethgen Olivier, Gathon Henry-Jean, Reginster Jean-Yves, Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women, 10.1016/j.bone.2008.08.119
  4. Kanis J. A., Johnell O., Oden A., Sernbo I., Redlund-Johnell I., Dawson A., De Laet C., Jonsson B., Long-Term Risk of Osteoporotic Fracture in Malmö, 10.1007/s001980070064
  5. Kanis J. A., , Odén A., McCloskey E. V., Johansson H., Wahl D. A., Cooper C., A systematic review of hip fracture incidence and probability of fracture worldwide, 10.1007/s00198-012-1964-3
  6. Kanis John A., Johnell Olof, De Laet Chris, Jonsson Bengt, Oden Anders, Ogelsby Alan K., International Variations in Hip Fracture Probabilities: Implications for Risk Assessment, 10.1359/jbmr.2002.17.7.1237
  7. Harvey Nicholas, Dennison Elaine, Cooper Cyrus, Osteoporosis: impact on health and economics, 10.1038/nrrheum.2009.260
  8. Ström O., Borgström F., Kanis John A., Compston Juliet, Cooper Cyrus, McCloskey Eugene V., Jönsson Bengt, Osteoporosis: burden, health care provision and opportunities in the EU : A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA), 10.1007/s11657-011-0060-1
  9. Kanis J. A., , McCloskey E. V., Johansson H., Cooper C., Rizzoli R., Reginster J.-Y., European guidance for the diagnosis and management of osteoporosis in postmenopausal women, 10.1007/s00198-012-2074-y
  10. International Network of Agencies of Health Technology Assessment (2012) INAHTA Health Technology Assessment Glossary. . Cited 1 April 2012
  11. Jonsson E., Banta D., Management of health technologies: an international view, 10.1136/bmj.319.7220.1293
  12. Banta David, Jonsson Egon, History of HTA: Introduction, 10.1017/s0266462309090321
  13. Martelli Francesco, Torre Giuseppe La, Ghionno Elena Di, Staniscia Tommaso, Neroni Massimo, Cicchetti Americo, Bremen Konrade Von, Ricciardi Walter, , Health technology assessment agencies: An international overview of organizational aspects, 10.1017/s026646230707064x
  14. Oliver Adam, Mossialos Elias, Robinson Ray, Health technology assessment and its influence on health-care priority setting, 10.1017/s026646230400073x
  15. Banta D, Oortwijn W (2000) Health technology assessment and health care in the European Union. Int J Technol Assess Health Care 16:626–635
  16. Goodman CS (2004) HTA 101: introduction to health technology assessment. . Cited 1 April 2012
  17. Melton L. Joseph, Chrischilles Elizabeth A., Cooper Cyrus, Lane Ann W., Riggs B. Lawrence, Perspective how many women have osteoporosis?, 10.1002/jbmr.5650070902
  18. van Staa T.P, Dennison E.M, Leufkens H.G.M, Cooper C, Epidemiology of fractures in England and Wales, 10.1016/s8756-3282(01)00614-7
  19. Dhanwal D. K., Cooper C., Dennison E. M., Geographic Variation in Osteoporotic Hip Fracture Incidence: The Growing Importance of Asian Influences in Coming Decades, 10.4061/2010/757102
  20. Johnell O., Borgstrom F., Jonsson B., Kanis J., Latitude, socioeconomic prosperity, mobile phones and hip fracture risk, 10.1007/s00198-006-0245-4
  21. Elffors I., Allander E., Kanis J. A., Gullberg B., Johnell O., Dequeker J., Dilsen G., Gennari C., Vaz A. A. Lopes, Lyritis G., Mazzuoli G. F., Miravet L., Passeri M., Cano R. Perez, Rapado A., Ribot C., The variable incidence of hip fracture in Southern Europe: The MEDOS study, 10.1007/bf01623349
  22. Roy D.K, Pye S.R, Lunt M, O’Neill T.W, Todd C, Raspe H, Reeve J, Silman A.J, Falls explain between-center differences in the incidence of limb fracture across Europe, 10.1016/s8756-3282(02)00909-2
  23. Langley J., Samaranayaka A., Davie G., Campbell A. J., Age, cohort and period effects on hip fracture incidence: analysis and predictions from New Zealand data 1974-2007, 10.1007/s00198-010-1205-6
  24. Cooper Cyrus, Martyn Christopher N, Prediction of burden of hip fracture, 10.1016/s0140-6736(98)00390-0
  25. Javaid MK, Crozier SR, Harvey NC, Gale CR, Dennison EM, Boucher BJ, Arden NK, Godfrey KM, Cooper C, Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study, 10.1016/s0140-6736(06)67922-1
  26. Cooper C., Campion G., Melton L. J., Hip fractures in the elderly: A world-wide projection, 10.1007/bf01623184
  27. Brauer Carmen A., Incidence and Mortality of Hip Fractures in the United States, 10.1001/jama.2009.1462
  28. Cooper C., , Cole Z. A., Holroyd C. R., Earl S. C., Harvey N. C., Dennison E. M., Melton L. J., Cummings S. R., Kanis J. A., Secular trends in the incidence of hip and other osteoporotic fractures, 10.1007/s00198-011-1601-6
  29. Melton L. J., Kearns A. E., Atkinson E. J., Bolander M. E., Achenbach S. J., Huddleston J. M., Therneau T. M., Leibson C. L., Secular trends in hip fracture incidence and recurrence, 10.1007/s00198-008-0742-8
  30. Hiligsmann Mickaël, Bruyère Olivier, Roberfroid Dominique, Dubois Cécile, Parmentier Yves, Carton Joëlle, Detilleux Johann, Gillet Pierre, Reginster Jean-Yves, Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007) : Hip Fracture Incidence and Change in Antiosteoporosis Medications, 10.1002/acr.21607
  31. Reginster JY, Gillet P, Gosset C (2001) Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ 79:942–946
  32. Abrahamsen B., Vestergaard P., Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006, 10.1007/s00198-009-0957-3
  33. Melton L Joseph, Kanis John A, Johnell Olof, Potential Impact of Osteoporosis Treatment on Hip Fracture Trends, 10.1359/jbmr.050308
  34. Rachner Tilman D, Khosla Sundeep, Hofbauer Lorenz C, Osteoporosis: now and the future, 10.1016/s0140-6736(10)62349-5
  35. Kanis J. A., Johnell O., Oden A., Johansson H., McCloskey E., FRAX™ and the assessment of fracture probability in men and women from the UK, 10.1007/s00198-007-0543-5
  36. Hiligsmann Mickaël, Rabenda Véronique, Bruyère Olivier, Reginster Jean-Yves, The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients, 10.1016/j.healthpol.2010.01.014
  37. Landfeldt Erik, Lundkvist Jonas, Ström Oskar, The societal burden of poor persistence to treatment of osteoporosis in Sweden, 10.1016/j.bone.2010.09.012
  38. Silverman Stuart L, Christiansen Claus, Genant Harry K, Vukicevic Slobodan, Zanchetta José R, de Villiers Tobie J, Constantine Ginger D, Chines Arkadi A, Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial*, 10.1359/jbmr.080710
  39. Cummings Steven R., Martin Javier San, McClung Michael R., Siris Ethel S., Eastell Richard, Reid Ian R., Delmas Pierre, Zoog Holly B., Austin Matt, Wang Andrea, Kutilek Stepan, Adami Silvano, Zanchetta Jose, Libanati Cesar, Siddhanti Suresh, Christiansen Claus, Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis, 10.1056/nejmoa0809493
  40. Reginster J-Y, Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study, 10.1136/ard.2005.044958
  41. Reginster J. Y., Seeman E., De Vernejoul M. C., Adami S., Compston J., Phenekos C., Devogelaer J. P., Curiel M. Diaz, Sawicki A., Goemaere S., Sorensen O. H., Felsenberg D., Meunier P. J., Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study, 10.1210/jc.2004-1774
  42. Black Dennis M., Delmas Pierre D., Eastell Richard, Reid Ian R., Boonen Steven, Cauley Jane A., Cosman Felicia, Lakatos Péter, Leung Ping Chung, Man Zulema, Mautalen Carlos, Mesenbrink Peter, Hu Huilin, Caminis John, Tong Karen, Rosario-Jansen Theresa, Krasnow Joel, Hue Trisha F., Sellmeyer Deborah, Eriksen Erik Fink, Cummings Steven R., Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis, 10.1056/nejmoa067312
  43. Cooper C., Reginster J.-Y., Cortet B., Diaz-Curiel M., Lorenc R.S., Kanis J.A., Rizzoli R., Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF), 10.1185/03007995.2012.663750
  44. Mazziotti G., Bilezikian J., Canalis E., Cocchi D., Giustina A., New understanding and treatments for osteoporosis, 10.1007/s12020-011-9570-2
  45. Devogelaer Jean-Pierre, Goemaere Stefan, Boonen Steven, Body Jean-Jacques, Kaufman Jean-Marc, Reginster Jean-Yves, Rozenberg Serge, Boutsen Yves, Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club, 10.1007/s00198-005-2032-z
  46. Body J.-J., Bergmann P., Boonen S., Boutsen Y., Devogelaer J.-P., Goemaere S., Kaufman J.-M., Rozenberg S., Reginster J.-Y., Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club, 10.1007/s00198-010-1223-4
  47. Marshall D., Johnell O., Wedel H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, 10.1136/bmj.312.7041.1254
  48. Kanis J. A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., Burckhardt P., Cooper C., Christiansen C., Cummings S., Eisman J. A., Fujiwara S., Glüer C., Goltzman D., Hans D., Krieg M.-A., La Croix A., McCloskey E., Mellstrom D., Melton L. J., Pols H., Reeve J., Sanders K., Schott A-M., Silman A., Torgerson D., van Staa T., Watts N. B., Yoshimura N., The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women, 10.1007/s00198-007-0343-y
  49. Ensrud Kristine E., A Comparison of Prediction Models for Fractures in Older Women : Is More Better?, 10.1001/archinternmed.2009.404
  50. Hippisley-Cox J., Coupland C., Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores, 10.1136/bmj.b4229
  51. Nguyen N. D., Frost S. A., Center J. R., Eisman J. A., Nguyen T. V., Development of a nomogram for individualizing hip fracture risk in men and women, 10.1007/s00198-007-0362-8
  52. Kanis J. A., Oden A., Johansson H., McCloskey E., Pitfalls in the external validation of FRAX, 10.1007/s00198-011-1846-0
  53. Kanis J. A., , Hans D., Cooper C., Baim S., Bilezikian J. P., Binkley N., Cauley J. A., Compston J. E., Dawson-Hughes B., El-Hajj Fuleihan G., Johansson H., Leslie W. D., Lewiecki E. M., Luckey M., Oden A., Papapoulos S. E., Poiana C., Rizzoli R., Wahl D. A., McCloskey E. V., Interpretation and use of FRAX in clinical practice, 10.1007/s00198-011-1713-z
  54. Leslie W. D., Lix L. M., Johansson H., Oden A., McCloskey E., Kanis J. A., Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement, 10.1007/s00198-010-1461-5
  55. Kanis J. A., Johansson H., Oden A., McCloskey E. V., Guidance for the adjustment of FRAX according to the dose of glucocorticoids, 10.1007/s00198-010-1524-7
  56. Gehlbach Stephen, Saag Kenneth G, Adachi Jonathan D, Hooven Fred H, Flahive Julie, Boonen Steven, Chapurlat Roland D, Compston Juliet E, Cooper Cyrus, Díez-Perez Adolfo, Greenspan Susan L, LaCroix Andrea Z, Netelenbos J Coen, Pfeilschifter Johannes, Rossini Maurizio, Roux Christian, Sambrook Philip N, Silverman Stuart, Siris Ethel S, Watts Nelson B, Lindsay Robert, Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women, 10.1002/jbmr.1476
  57. Black Dennis M., Arden Nigel K., Palermo Lisa, Pearson Jim, Cummings Steven R., Prevalent Vertebral Deformities Predict Hip Fractures and New Vertebral Deformities but Not Wrist Fractures, 10.1359/jbmr.1999.14.5.821
  58. Kayan K., Johansson H., Oden A., Vasireddy S., Pande K., Orgee J., Kanis J. A., McCloskey E. V., Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate, 10.1007/s00198-009-0942-x
  59. Huybrechts Krista F., Ishak Khajak J., Caro J. Jaime, Assessment of compliance with osteoporosis treatment and its consequences in a managed care population, 10.1016/j.bone.2005.10.022
  60. Rabenda V., Mertens R., Fabri V., Vanoverloop J., Sumkay F., Vannecke C., Deswaef A., Verpooten G. A., Reginster J.-Y., Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women, 10.1007/s00198-007-0506-x
  61. Weycker D., Macarios D., Edelsberg J., Oster G., Compliance with drug therapy for postmenopausal osteoporosis, 10.1007/s00198-006-0179-x
  62. Rabenda Véronique, Reginster Jean-Yves, Overcoming problems with adherence to osteoporosis medication, 10.1586/erp.10.76
  63. Ross Susan, Samuels Ebony, Gairy Kerry, Iqbal Sheikh, Badamgarav Enkhe, Siris Ethel, A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence, 10.1016/j.jval.2010.11.010
  64. Hiligsmann Mickaël, McGowan Bernie, Bennett Kathleen, Barry Michael, Reginster Jean-Yves, The Clinical and Economic Burden of Poor Adherence and Persistence with Osteoporosis Medications in Ireland, 10.1016/j.jval.2012.02.001
  65. Gleeson T., Iversen M. D., Avorn J., Brookhart A. M., Katz J. N., Losina E., May F., Patrick A. R., Shrank W. H., Solomon D. H., Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review, 10.1007/s00198-009-0976-0
  66. Hiligsmann M., Salas M., Hughes D.A., Manias E., Gwadry-Sridhar F., Linck P., Cowell W., PMS39 MOST EFFECTIVE ADHERENCE-ENHANCING INTERVENTIONS FOR OSTEOPOROSIS MEDICATIONS, 10.1016/j.jval.2011.02.724
  67. Freemantle N., , Satram-Hoang S., Tang E.-T., Kaur P., Macarios D., Siddhanti S., Borenstein J., Kendler D. L., Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women, 10.1007/s00198-011-1780-1
  68. Montori Victor M., Shah Nilay D., Pencille Laurie J., Branda Megan E., Van Houten Holly K., Swiglo Brian A., Kesman Rebecca L., Tulledge-Scheitel Sidna M., Jaeger Thomas M., Johnson Ruth E., Bartel Gregory A., Melton L. Joseph, Wermers Robert A., Use of a Decision Aid to Improve Treatment Decisions in Osteoporosis: The Osteoporosis Choice Randomized Trial, 10.1016/j.amjmed.2011.01.013
  69. Nielsen Dorthe, Ryg Jesper, Nielsen Winnie, Knold Berit, Nissen Nis, Brixen Kim, Patient education in groups increases knowledge of osteoporosis and adherence to treatment: A two-year randomized controlled trial, 10.1016/j.pec.2010.03.010
  70. Drummond M, Sculpher M, O’Brien B, Stoddart G, Torrance G (2007) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, New York
  71. Taylor R S, Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle, 10.1136/bmj.329.7472.972
  72. Drummond Michael, Jönsson Bengt, Rutten Frans, The role of economic evaluation in the pricing and reimbursement of medicines, 10.1016/s0168-8510(97)00901-9
  73. Cleemput Irina, van Wilder Philippe, Huybrechts Michel, Vrijens France, Belgian Methodological Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Requests, 10.1111/j.1524-4733.2008.00469.x
  74. Kanis J. A., Cooper C., Hiligsmann M., Rabenda V., Reginster J-Y., Rizzoli R., Partial adherence: a new perspective on health economic assessment in osteoporosis, 10.1007/s00198-011-1668-0
  75. Palmer S., Byford S., Raftery J., Economics Notes: Types of economic evaluation, 10.1136/bmj.318.7194.1349
  76. Zethraeus N., Borgström F., Ström O., Kanis J. A., Jönsson B., Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model, 10.1007/s00198-006-0257-0
  77. Briggs A, Claxton K, Sculpher M (2007) Decision modelling for health economic evaluation, 2nd edn. Oxford University Press, New York
  78. Raftery J., NICE: faster access to modern treatments? Analysis of guidance on health technologies, 10.1136/bmj.323.7324.1300
  79. World Health Organization (2011) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. . Cited 10 April 2012
  80. Lippuner K., Johansson H., Borgström F., Kanis J. A., Rizzoli R., Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland, 10.1007/s00198-011-1869-6
  81. Borgström F., Johnell O., Kanis J. A., Jönsson B., Rehnberg C., At what hip fracture risk is it cost-effective to treat? : International intervention thresholds for the treatment of osteoporosis, 10.1007/s00198-006-0107-0
  82. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M (2008) Threshold values for cost-effectiveness in health care. Health technology assessment (HTA). KCE Reports 100B (D/2008/10.273/95). Belgian Health Care Knowledge Centre, Brussels
  83. George Bethan, Harris Anthony, Mitchell Andrew, Cost-Effectiveness Analysis and the Consistency of Decision Making : Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996), 10.2165/00019053-200119110-00004
  84. Devlin Nancy, Parkin David, Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, 10.1002/hec.864
  85. National institute for Health and Clinical Excellence (2012) Appraising life-extending, end of life treatments. . Cited 10 April 2012
  86. Petrou S., Gray A., Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting, 10.1136/bmj.d1548
  87. Petrou S., Gray A., Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting, 10.1136/bmj.d1766
  88. OBrien B (1996) Economic evaluation of pharmaceuticals. Frankenstein’s monster or vampire of trials? Med Care 34:DS99–DS108
  89. Sculpher Mark J., Claxton Karl, Drummond Mike, McCabe Chris, Whither trial-based economic evaluation for health care decision making?, 10.1002/hec.1093
  90. Brennan Alan, Akehurst Ron, Modelling in Health Economic Evaluation : What is its Place? What is its Value?, 10.2165/00019053-200017050-00004
  91. Buxton Martin J., Drummond Michael F., Van Hout Ben A., Prince Richard L., Sheldon Trevor A., Szucs Thomas, Vray Muriel, Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life, 10.1002/(sici)1099-1050(199705)6:3<217::aid-hec267>;2-w
  92. Sheldon Trevor A., Problems of using modelling in the economic evaluation of health care, 10.1002/(sici)1099-1050(199601)5:1<1::aid-hec183>;2-k
  93. Kassirer Jerome P., Angell Marcia, The Journal's Policy on Cost-Effectiveness Analyses, 10.1056/nejm199409083311009
  94. National Institute for Health and Clinical Excellence (2010) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.
  95. Kanis John A., McCloskey Eugene V., Jonsson Bengt, Cooper Alun, Ström Oskar, Borgström Fredrik, An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women, 10.1007/s11657-010-0045-5
  96. Fleurence Rachael L., Spackman D. Eldon, Hollenbeak Christopher, Does the Funding Source Influence the Results in Economic Evaluations? : A Case Study in Bisphosphonates for the Treatment of Osteoporosis, 10.2165/11530530-000000000-00000
  97. &NA;, Decision Analytic Modelling in the Economic Evaluation of Health Technologies : A Consensus Statement, 10.2165/00019053-200017050-00003
  98. Hiligsmann Mickaël, Reginster Jean-Yves, Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium : , 10.2165/11539980-000000000-00000
  99. Fenwick Elisabeth, O'Brien Bernie J., Briggs Andrew, Cost-effectiveness acceptability curves– facts, fallacies and frequently asked questions, 10.1002/hec.903
  100. Sonnenberg Frank A., Beck J. Robert, Markov Models in Medical Decision Making : A Practical Guide, 10.1177/0272989x9301300409
  101. Hiligsmann Mickaël, Ethgen Olivier, Bruyère Olivier, Richy Florent, Gathon Henry-Jean, Reginster Jean-Yves, Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis, 10.1111/j.1524-4733.2008.00497.x
  102. Müller Dirk, Pulm Jannis, Gandjour Afschin, Cost-Effectiveness of Different Strategies for Selecting and Treating Individuals at Increased Risk of Osteoporosis or Osteopenia: A Systematic Review, 10.1016/j.jval.2011.11.030
  103. Zethraeus N., Ben Sedrine W., Caulin F., Corcaud S., Gathon H. J., Haim M., Johnell O., Jönsson B., Kanis J. A., Tsouderos Y., Reginster J.-Y., Models for Assessing the Cost-Effectiveness of the Treatment and Prevention of Osteoporosis, 10.1007/s001980200117
  104. Hiligsmann M, Reginster JY (2012) Health economics in osteoporosis. Temas de osteoporosis y otras enfermedades oseas. 337–358
  105. Fleurence Rachael L, Iglesias Cynthia P, Johnson Jeanene M, The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis : A Structured Review of the Literature, 10.2165/00019053-200725110-00003
  106. Fleurence Rachael L., Iglesias Cynthia P., Torgerson David J., Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature, 10.1007/s00198-005-1943-z
  107. Schousboe John T, Cost Effectiveness of Screen-and-Treat Strategies for Low Bone Mineral Density : How Do We Screen, Who Do We Screen and Who Do We Treat?, 10.2165/00148365-200806010-00001
  108. Hiligsmann M., Bruyère O., Reginster J.-Y., Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women, 10.1007/s00198-009-0924-z
  109. Hiligsmann Mickaël, Reginster Jean-Yves, Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women, 10.1016/j.bone.2010.03.009
  110. Borgström Fredrik, Kanis John A., Health economics of osteoporosis, 10.1016/j.beem.2008.07.005
  111. Jönsson B., Ström O., Eisman J. A., Papaioannou A., Siris E. S., Tosteson A., Kanis J. A., Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis, 10.1007/s00198-010-1424-x
  112. Hiligsmann Mickaël, Bruyère Olivier, Reginster Jean-Yves, Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years, 10.1016/j.bone.2009.08.052
  113. Akehurst R., Brereton N., Ariely R., Lusa T., Groot M., Foss P., Boonen S., The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands, 10.3111/13696998.2010.545563
  114. Cranney Ann, Guyatt Gordon, Griffith Lauren, Wells George, Tugwell Peter, Rosen Clifford, IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis, 10.1210/er.2001-9002
  115. Kanis John A., McCloskey Eugene, Johansson Helena, Oden Anders, Leslie William D., FRAX® with and without Bone Mineral Density, 10.1007/s00223-011-9544-7
  116. Ström O., Borgström F., Kleman M., McCloskey E., Odén A., Johansson H., Kanis J.A., FRAX® and its applications in health economics—Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example, 10.1016/j.bone.2010.05.020
  117. Kanis J. A., McCloskey E. V., Johansson H., Strom O., Borgstrom F., Oden A., , Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK, 10.1007/s00198-008-0712-1
  118. Tosteson A. N. A., Melton L. J., Dawson-Hughes B., Baim S., Favus M. J., Khosla S., Lindsay R. L., Cost-effective osteoporosis treatment thresholds: the United States perspective, 10.1007/s00198-007-0550-6
  119. Johansson H., Kanis J. A., McCloskey E. V., Odén A., Devogelaer J.-P., Kaufman J.-M., Neuprez A., Hiligsmann M., Bruyere O., Reginster J.-Y., A FRAX® model for the assessment of fracture probability in Belgium, 10.1007/s00198-010-1218-1
  120. Danese Mark D, Badamgarav Enkhe, Bauer Douglas C, Effect of Adherence on Lifetime Fractures in Osteoporotic Women Treated With Daily and Weekly Bisphosphonates, 10.1359/jbmr.090506
  121. Cotté François-Emery, Cortet Bernard, Lafuma Antoine, Avouac Bernard, Hasnaoui Abdelkader El, Fardellone Patrice, Pouchain Denis, Roux Christian, Gaudin Anne-Françoise, A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France, 10.1016/j.jbspin.2007.06.004
  122. Hiligsmann Mickaël, Rabenda Véronique, Gathon Henry-Jean, Ethgen Olivier, Reginster Jean-Yves, Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications, 10.1007/s00223-009-9329-4
  123. Rietbrock S., Olson M., van Staa T.P., The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates, 10.1093/qjmed/hcn130
  124. Patrick Amanda R., Schousboe John T., Losina Elena, Solomon Daniel H., The Economics of Improving Medication Adherence in Osteoporosis: Validation and Application of a Simulation Model, 10.1210/jc.2011-0575
  125. Ström O., Borgström F., Kanis J. A., Jönsson B., Incorporating adherence into health economic modelling of osteoporosis, 10.1007/s00198-008-0644-9
  126. Hiligsmann Mickaël, Boonen Annelies, Rabenda Véronique, Reginster Jean-Yves, The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis, 10.1586/erp.12.8
  127. Hutton John, Trueman Paul, Facey Karen, Harmonization of evidence requirements for health technology assessment in reimbursement decision making, 10.1017/s0266462308080677
  128. Drummond Michael, Barbieri Marco, Cook John, Glick Henry A., Lis Joanna, Malik Farzana, Reed Shelby D., Rutten Frans, Sculpher Mark, Severens Johan, Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report, 10.1111/j.1524-4733.2008.00489.x
  129. Drummond MF, Schwartz JS, Jonsson B et al (2008) Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 24(244–258):362–368
  130. Weinstein Milton C, Recent Developments in Decision-Analytic Modelling for Economic Evaluation : , 10.2165/00019053-200624110-00002
  131. Hoaglin David C., Hawkins Neil, Jansen Jeroen P., Scott David A., Itzler Robbin, Cappelleri Joseph C., Boersma Cornelis, Thompson David, Larholt Kay M., Diaz Mireya, Barrett Annabel, Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2, 10.1016/j.jval.2011.01.011
  132. Darbà J., Restovic G., Kaskens L., Balbona M. A., Carbonell A., Cavero P., Jordana M., Prieto C., Molina Á., Padró I., Patient preferences for osteoporosis in Spain: a discrete choice experiment, 10.1007/s00198-010-1382-3
  133. de Bekker-Grob E. W., Essink-Bot M. L., Meerding W. J., Pols H. A. P., Koes B. W., Steyerberg E. W., Patients’ preferences for osteoporosis drug treatment: a discrete choice experiment, 10.1007/s00198-007-0535-5
  134. Lancsar Emily, Louviere Jordan, Conducting Discrete Choice Experiments to Inform Healthcare Decision Making : A User??s Guide, 10.2165/00019053-200826080-00004
  135. Ryan M., Discrete choice experiments in health care, 10.1136/bmj.328.7436.360
  136. Humphreys K., Piot P., Scientific evidence alone is not sufficient basis for health policy, 10.1136/bmj.e1316